ReviewAnnals of translational medicine2016
Companion diagnostics-a tool to improve pharmacotherapy.
Review in Annals of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 68 citations in OpenAlex.
- Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions.MedComm · 2026Review
- Bone-on-a-Chip Systems for Hematological Cancers.Biosensors · 2025Review
- Insights into post-marketing clinical validation of companion diagnostics with reference to the FDA, EMA, PMDA, and MFDS.Molecular therapy. Methods & clinical development · 2024Review
- Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives.Biomedicines · 2024Review
- Review
- How to START? Four pillars to optimally begin your orphan drug development.Orphanet journal of rare diseases · 2023Article
- HSF1 is a driver of leukemia stem cell self-renewal in acute myeloid leukemia.Nature communications · 2022Article
- Differentiating between UCTD and early-stage SLE: from definitions to clinical approach.Nature reviews. Rheumatology · 2022Review
- Review
- Pathogenesis and Management of COVID-19.Journal of xenobiotics · 2021Review
- Companion Diagnostics: State of the Art and New Regulations.Biomarker insights · 2021Review
- Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics.Frontiers in pharmacology · 2021Review
- Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.Journal for immunotherapy of cancer · 2020Article
- The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors.International journal of molecular sciences · 2020Review
- Differential Dependency of Human Pancreatic Cancer Cells on Targeting PTEN via PLK 1 Expression.Cancers · 2020Article
- Preparation of the standard cell lines for reference mutations in cancer gene-panels by genome editing in HEK 293 T/17 cells.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2020Article
- Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.BMC cancer · 2019Article
- Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy.The oncologist · 2019Article
- A paradigm shift in biomarker guided oncology drug development.Annals of translational medicine · 2019Review
- Artificial intelligence and machine learning in clinical development: a translational perspective.NPJ digital medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The variability of pharmacotherapy can be of a significant magnitude, and the main reason for this is often diseases heterogeneity. Patients who have similar diagnoses very often respond differently to the same pharmacological intervention, with great variability in both efficacy and safety outcome. Despite having discussed personalized medicine for more than a decade, we still see that most drug prescriptions for severe chronic diseases are largely based on 'trial and error' and not on solid biomarker data. However, with the advance of molecular diagnostics and a subsequent increased understanding of disease mechanisms, things are slowly changing. Within the last few years, we have seen an increasing number of predictive biomarker assays being developed to guide the use of targeted cancer drugs. This type of assay is called companion diagnostics and is developed in parallel to the drug using the drug-diagnostic co-development model. The development of companion diagnostics is a relatively new discipline and in this review, different aspects will be discussed including clinical and regulatory issues. Furthermore, examples of drugs, such as the ALK and PD-1/PD-L1 inhibitors, that have been approved recently together with a companion or complimentary diagnostic will be given.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.